Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI
Status:
Recruiting
Trial end date:
2025-06-10
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multicenter, phase II study to evaluate the efficacy and
safety of SY-3505 capsule in patients with locally advanced or metastatic NSCLC who have
progressed on or are intolerant to second-generation ALK tyrosine kinase inhibitor (TKI).